Tabrecta (Capmatinib Hydrochloride) Patent Expiration, LOE Window & CMS Spending

Tabrecta (Capmatinib Hydrochloride) by Novartis: FDA Orange Book core substance LOE 2032-11-19 (last listed 2035-07-22), 0 AB generics, $130.0M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorNovartis
FDA Application & PathwayN213591 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-11-19
Last Listed Patent or Exclusivity Date2035-07-22
Orange Book Patents (*PED Extensions)7 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$130.0M
2024 Medicare Part D Spend$124.1M
2024 Medicaid Spend$5.9M
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 20.2% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Novartis across sibling Meru public-data platforms.